Afficher la couverture 'Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial | Rouzier, Roman' en grand format
/5

0 avis

Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial

Archive ouverte

Rouzier, Roman | Gouy, Sébastien | Selle, Frédéric | Lambaudie, Eric | Floquet, Anne | Fourchotte, Virginie | Pomel, Christophe | Colombo, Pierre-Emmanuel | Kalbacher, Elsa | Martin-Francoise, Sandrine | Fauvet, Raffaèle | Follana, Philippe | Lesoin, Anne | Lecuru, Fabrice | Ghazi, Youssef | Dupin, Julien | Chéreau, Elisabeth | Zohar, Sarah | Cottu, Paul | Joly, Florence

Edité par CCSD ; Elsevier -

International audience. To investigate whether adding bevacizumab to neoadjuvant carboplatin-paclitaxel (CP) helps achieve optimal debulking, measured by complete resection rate (CRR) at interval debulking surgery (IDS), in patients with initially unresectable International Federation of Gynecology and Obstetrics stage IIIC/IV ovarian, tubal or peritoneal adenocarcinoma.

Consulter en ligne

Suggestions

Du même auteur

[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].. Préservation de la fertilité, contraception et traitement hormonal de la ménopause chez les femmes traitées pour tumeurs malignes rares de l’ovaire : recommandations du réseau national dédié aux cancers gynécologiques rares (TMRG/GINECO)

Archive ouverte | Rousset-Jablonski, Christine | CCSD

National audience. Introduction - Rare ovarian tumors include complex borderline ovarian tumors, sex-cord tumors, germ cell tumors, and rare epithelial tumors. Indications and modalities of fertility preservation, i...

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

Archive ouverte | Harter, P. | CCSD

International audience. The use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) i...

739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial. L’année 2021 dans tous ses états : une synthèse digérée

Archive ouverte | Sabatier, Renaud | CCSD

International audience. 5548 Background: Ovarian cancer is the leading cause of death by gynecological cancer. Complete surgery remains one of the main prognostic factors. Laparoscopic exploration is mandatory to as...

Chargement des enrichissements...